These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 24004819)

  • 1. Mammary carcinoma cell derived cyclooxygenase 2 suppresses tumor immune surveillance by enhancing intratumoral immune checkpoint activity.
    Markosyan N; Chen EP; Evans RA; Ndong V; Vonderheide RH; Smyth EM
    Breast Cancer Res; 2013; 15(5):R75. PubMed ID: 24004819
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Myeloid Cell COX-2 deletion reduces mammary tumor growth through enhanced cytotoxic T-lymphocyte function.
    Chen EP; Markosyan N; Connolly E; Lawson JA; Li X; Grant GR; Grosser T; FitzGerald GA; Smyth EM
    Carcinogenesis; 2014 Aug; 35(8):1788-97. PubMed ID: 24590894
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Deletion of cyclooxygenase 2 in mouse mammary epithelial cells delays breast cancer onset through augmentation of type 1 immune responses in tumors.
    Markosyan N; Chen EP; Ndong VN; Yao Y; Sterner CJ; Chodosh LA; Lawson JA; Fitzgerald GA; Smyth EM
    Carcinogenesis; 2011 Oct; 32(10):1441-9. PubMed ID: 21771729
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade.
    Zhu Y; Yang J; Xu D; Gao XM; Zhang Z; Hsu JL; Li CW; Lim SO; Sheng YY; Zhang Y; Li JH; Luo Q; Zheng Y; Zhao Y; Lu L; Jia HL; Hung MC; Dong QZ; Qin LX
    Gut; 2019 Sep; 68(9):1653-1666. PubMed ID: 30902885
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual CTLA-4 and PD-L1 Blockade Inhibits Tumor Growth and Liver Metastasis in a Highly Aggressive Orthotopic Mouse Model of Colon Cancer.
    Fiegle E; Doleschel D; Koletnik S; Rix A; Weiskirchen R; Borkham-Kamphorst E; Kiessling F; Lederle W
    Neoplasia; 2019 Sep; 21(9):932-944. PubMed ID: 31412307
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
    Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
    Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of T-cell-mediated immune response via the PD-1/ PD-L1 axis in cholangiocarcinoma cells.
    Suriyo T; Fuangthong M; Artpradit C; Ungtrakul T; Sricharunrat T; Taha F; Satayavivad J
    Eur J Pharmacol; 2021 Apr; 897():173960. PubMed ID: 33617828
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunological differences between primary and metastatic breast cancer.
    Szekely B; Bossuyt V; Li X; Wali VB; Patwardhan GA; Frederick C; Silber A; Park T; Harigopal M; Pelekanou V; Zhang M; Yan Q; Rimm DL; Bianchini G; Hatzis C; Pusztai L
    Ann Oncol; 2018 Nov; 29(11):2232-2239. PubMed ID: 30203045
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor cell-released autophagosomes (TRAPs) promote immunosuppression through induction of M2-like macrophages with increased expression of PD-L1.
    Wen ZF; Liu H; Gao R; Zhou M; Ma J; Zhang Y; Zhao J; Chen Y; Zhang T; Huang F; Pan N; Zhang J; Fox BA; Hu HM; Wang LX
    J Immunother Cancer; 2018 Dec; 6(1):151. PubMed ID: 30563569
    [TBL] [Abstract][Full Text] [Related]  

  • 10. COX-2 and PGE2-dependent immunomodulation in breast cancer.
    Chen EP; Smyth EM
    Prostaglandins Other Lipid Mediat; 2011 Nov; 96(1-4):14-20. PubMed ID: 21907301
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
    Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
    Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
    [No Abstract]   [Full Text] [Related]  

  • 12. Progranulin induces immune escape in breast cancer via up-regulating PD-L1 expression on tumor-associated macrophages (TAMs) and promoting CD8
    Fang W; Zhou T; Shi H; Yao M; Zhang D; Qian H; Zeng Q; Wang Y; Jin F; Chai C; Chen T
    J Exp Clin Cancer Res; 2021 Jan; 40(1):4. PubMed ID: 33390170
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neutrophil Extracellular Traps Promote T Cell Exhaustion in the Tumor Microenvironment.
    Kaltenmeier C; Yazdani HO; Morder K; Geller DA; Simmons RL; Tohme S
    Front Immunol; 2021; 12():785222. PubMed ID: 34899751
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antitumor immunity is defective in T cell-specific microRNA-155-deficient mice and is rescued by immune checkpoint blockade.
    Huffaker TB; Lee SH; Tang WW; Wallace JA; Alexander M; Runtsch MC; Larsen DK; Thompson J; Ramstead AG; Voth WP; Hu R; Round JL; Williams MA; O'Connell RM
    J Biol Chem; 2017 Nov; 292(45):18530-18541. PubMed ID: 28912267
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune phenotype of patients with stage IV metastatic inflammatory breast cancer.
    Fernandez SV; MacFarlane AW; Jillab M; Arisi MF; Yearley J; Annamalai L; Gong Y; Cai KQ; Alpaugh RK; Cristofanilli M; Campbell KS
    Breast Cancer Res; 2020 Dec; 22(1):134. PubMed ID: 33267869
    [TBL] [Abstract][Full Text] [Related]  

  • 16. WDR5-H3K4me3 epigenetic axis regulates OPN expression to compensate PD-L1 function to promote pancreatic cancer immune escape.
    Lu C; Liu Z; Klement JD; Yang D; Merting AD; Poschel D; Albers T; Waller JL; Shi H; Liu K
    J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34326167
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CaMKK2 in myeloid cells is a key regulator of the immune-suppressive microenvironment in breast cancer.
    Racioppi L; Nelson ER; Huang W; Mukherjee D; Lawrence SA; Lento W; Masci AM; Jiao Y; Park S; York B; Liu Y; Baek AE; Drewry DH; Zuercher WJ; Bertani FR; Businaro L; Geradts J; Hall A; Means AR; Chao N; Chang CY; McDonnell DP
    Nat Commun; 2019 Jun; 10(1):2450. PubMed ID: 31164648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transforming growth factor beta orchestrates PD-L1 enrichment in tumor-derived exosomes and mediates CD8 T-cell dysfunction regulating early phosphorylation of TCR signalome in breast cancer.
    Chatterjee S; Chatterjee A; Jana S; Dey S; Roy H; Das MK; Alam J; Adhikary A; Chowdhury A; Biswas A; Manna D; Bhattacharyya A
    Carcinogenesis; 2021 Feb; 42(1):38-47. PubMed ID: 32832992
    [TBL] [Abstract][Full Text] [Related]  

  • 19. COX-2 Inhibitors Decrease Expression of PD-L1 in Colon Tumors and Increase the Influx of Type I Tumor-infiltrating Lymphocytes.
    Cecil DL; Gad EA; Corulli LR; Drovetto N; Lubet RA; Disis ML
    Cancer Prev Res (Phila); 2022 Apr; 15(4):225-231. PubMed ID: 34987061
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progesterone promotes immunomodulation and tumor development in the murine mammary gland.
    Werner LR; Gibson KA; Goodman ML; Helm DE; Walter KR; Holloran SM; Trinca GM; Hastings RC; Yang HH; Hu Y; Wei J; Lei G; Yang XY; Madan R; Molinolo AA; Markiewicz MA; Chalise P; Axelrod ML; Balko JM; Hunter KW; Hartman ZC; Lange CA; Hagan CR
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33958486
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.